BioMarin Pharmaceutical Inc. (BIT:1BMRN)
Italy flag Italy · Delayed Price · Currency is EUR
54.82
0.00 (0.00%)
At close: Mar 2, 2026

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
VOXZOGO Revenue
926.92M735.09M
VOXZOGO Revenue Growth
26.10%56.44%
VIMIZIM Revenue
792.05M739.78M
VIMIZIM Revenue Growth
7.07%5.53%
NAGLAZYME Revenue
485.40M479.58M
NAGLAZYME Revenue Growth
1.21%14.11%
PALYNZIQ Revenue
433.31M355.05M
PALYNZIQ Revenue Growth
22.04%16.82%
ALDURAZYME Revenue
208.51M183.89M
ALDURAZYME Revenue Growth
13.39%40.11%
BRINEURA Revenue
186.40M169.08M
BRINEURA Revenue Growth
10.24%4.44%
KUVAN Revenue
99.53M120.90M
KUVAN Revenue Growth
-17.68%-33.12%
ROCTAVIAN Revenue
35.64M26.07M
ROCTAVIAN Revenue Growth
36.73%647.09%
Total Net Product Revenue
3.17B2.81B
Total Net Product Revenue Growth
12.75%18.41%
Royalty and Other Revenue
53.49M44.47M
Royalty and Other Revenue Growth
20.29%-4.75%
Revenue (Total)
3.22B2.85B
Revenue (Total) Growth
12.87%17.97%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Royalty and Other Revenue
53.49M44.47M
Royalty and Other Revenue Growth
20.29%-4.75%
United States Revenue
1.10B924.81M
United States Revenue Growth
19.48%19.90%
Europe Revenue
874.33M829.03M
Europe Revenue Growth
5.46%23.86%
Latin America Revenue
435.48M378.08M
Latin America Revenue Growth
15.18%13.73%
Rest of World Revenue (Post-Q2 2024)
544.47M493.63M
Rest of World Revenue (Post-Q2 2024) Growth
10.30%5.43%
Revenue (Other)
208.51M183.89M
Revenue (Total)
3.22B2.85B
Revenue (Total) Growth
12.87%17.97%
Updated Dec 31, 2025. Data Source: Fiscal.ai.